Svennilson Peter
Follow13F filer, CIK 1606074, SAN FRANCISCO, CA
Svennilson Peter reported $1,195,756,000 across 7 holdings for the quarter ended 2020-06-30, in a 13F-HR filed 2020-08-12.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-20-008388
- Period
- 2020-06-30
- Reported value
- $1.2B
- Holdings
- 7
- Top 10 weight
- 100%
- New
- 1
- Sold out
- 0
Stakes and trades reported after 2020-06-30
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- SRZN SURROZEN INC: 13D/A 3,813,501 shares, 18.2% of the class, 13D/A filed 2026-11-18, 0001193125-26-467393Timeline
Accepted , ingested - TNYA TENAYA THERAPEUTICS INC: 13D/A 49,313,559 shares, 21.6% of the class, 13D/A filed 2026-11-16, 0001193125-26-463722Timeline
Accepted , ingested
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| ORICnew | +4,768,181 | $161M |
| NGM BIOPHARMACEUTICALS INCadded | +383,834 | $7.58M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| RCUSreduced | -1,773,174 | -$43.9M |
| GRITSTONE BIO INCreduced | -1,401,989 | -$9.31M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q2 2020
Share positions as resolved from 13F-HR 0000950123-20-008388, largest first. % of portfolio is the value over $1,195,756,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INC | 17,706,978 | $350M | 29.23% | +383,834 | |||
| RVMDREVOLUTION MEDICINES INC | 7,977,384 | $252M | 21.06% | 0 | Timeline | ||
| RAPT THERAPEUTICS INCRAPT THERAPEUTICS INC | 6,777,151 | $197M | 16.45% | 0 | |||
| CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICAL | 6,051,376 | $182M | 15.21% | 0 | |||
| ORICORIC PHARMACEUTICALS INC | 4,768,181 | $161M | 13.45% | new | Timeline | ||
| RCUSARCUS BIOSCIENCES INC | 1,767,676 | $43.7M | 3.66% | -1,773,174 | Timeline | ||
| GRITSTONE BIO INCGRITSTONE BIO INC | 1,700,945 | $11.3M | 0.94% | -1,401,989 |
How Q2 2020 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000950123-20-008388 | base | 2020-08-12 | acceptance time not in the bulk data set |